Stocks Health care KNSA
NASDAQ · Health careKiniksa Pharmaceuticals International, plc (KNSA)
Kiniksa Pharmaceuticals International, plc brought in $946M of revenue over the twelve months to September 30, 2026, up 58.2% from a year earlier. Net income was $109.6M, a net margin of 11.6%. Operating cash flow minus capital spending left $136.4M of free cash flow in fiscal 2025. At September 30, 2026 it held $81.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 27, 2026.
Key facts about Kiniksa Pharmaceuticals International, plc
- Net worth
- Kiniksa Pharmaceuticals International, plc has a market value (market cap) of $7.4B at the latest share price, and shareholders' equity of $710.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $677.6M (+60.1% year on year), with net income of $59M. Over the 12 months to September 30, 2026: revenue $946M, net income $109.6M.
- Cash flow
- In fiscal 2025 operations brought in $138M of cash; after $1.6M of capital spending, free cash flow was $136.4M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 27, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Kiniksa Pharmaceuticals International, plc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Kiniksa Pharmaceuticals International, plc does
Kiniksa Pharmaceuticals International, plc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KNSA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $677.6M | $59M | $0.75 | $136.4M |
| 2024 | $423.2M | -$43.2M | -$0.60 | $25.4M |
| 2023 | $270.3M | $14.1M | $0.20 | $13.2M |
| 2022 | $220.2M | $183.4M | $2.60 | $5.7M |
| 2021 | $38.5M | -$157.9M | -$2.30 | -$126.7M |
| 2020 | n/a | -$161.4M | -$2.61 | -$136.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where KNSA ranks in Health care
Latest SEC filings
What Kiniksa Pharmaceuticals International, plc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 27, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 58% to $286M versus the same quarter last year; diluted EPS $0.56 versus $0.23.
- October 27, 2026
- October 22, 2026
- July 29, 2026Passive stake (5% or more) SCHEDULE 13G
- July 28, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 55% to $243.6M versus the same quarter last year; diluted EPS $0.30 versus $0.23.
- July 28, 2026
- May 29, 2026
- May 26, 2026Activist stake changed SCHEDULE 13D/A
- May 26, 2026
- May 6, 2026Passive stake changed SCHEDULE 13G/A
What is KNSA worth? A DCF from its reported cash flow
Insider trades
What the people running Kiniksa Pharmaceuticals International, plc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $77.5M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 4, 2026 | Patel Sanj KCHAIRMAN & CEO, Director | Exercised optionsindirect | 145,763 | $2.6M |
| November 4, 2026 | Patel Sanj KCHAIRMAN & CEO, Director | Soldpre-planned (10b5-1), indirect | 1,460 | $134.8K |
| November 4, 2026 | Patel Sanj KCHAIRMAN & CEO, Director | Soldpre-planned (10b5-1), indirect | 11,335 | $1.1M |
| November 4, 2026 | Patel Sanj KCHAIRMAN & CEO, Director | Soldpre-planned (10b5-1), indirect | 81,742 | $7.7M |
| November 4, 2026 | Patel Sanj KCHAIRMAN & CEO, Director | Soldpre-planned (10b5-1), indirect | 29,845 | $2.8M |
| November 4, 2026 | Patel Sanj KCHAIRMAN & CEO, Director | Soldpre-planned (10b5-1), indirect | 26,918 | $2.6M |
| November 3, 2026 | Patel Sanj KCHAIRMAN & CEO, Director | Exercised optionsindirect | 89,089 | $786.7K |
| November 3, 2026 | Patel Sanj KCHAIRMAN & CEO, Director | Exercised optionsindirect | 41,237 | $739K |
Who owns KNSA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 14.8% | May 6, 2026 |
| Rubric Capital Management LP13G, passive with 1 related filers | 7.37% | February 13, 2026 |
| Julian C. Baker13D, may seek influence with 4 related filers | 7% | May 26, 2026 |
| Tang Capital Management, LLC13G, passive with 5 related filers | 5.2% | April 4, 2025 |
Largest institutional holders
Insiders
13 insiders reported holding 3,744,602 shares in total, about $355.8M at the last price.
| Holder | Shares |
|---|---|
| Baker Bros. Advisors LPDirector | 2,744,8942,744,894 held indirectly |
| Patel Sanj KCHAIRMAN & CEO, Director | 774,500774,500 held indirectly |
| Paolini John F.CHIEF MEDICAL OFFICER | 69,922 |
| Tessari EbenCHIEF STRATEGY OFFICER | 23,130 |
| Levy Richard SDirector | 22,359 |
| Ragosa MarkCHIEF FINANCIAL OFFICER | 20,854 |
| Popovits Kimberly JDirector | 15,345 |
| McCain Tracey LDirector | 15,345 |
| Malley ThomasDirector | 15,345 |
| Quart Barry DDirector | 12,745 |
Questions about KNSA
What does Kiniksa Pharmaceuticals International, plc do?
Kiniksa Pharmaceuticals International, plc is a company in the Health care sector, listed on NASDAQ as KNSA. Its shares trade on NASDAQ under the ticker KNSA.
What is Kiniksa Pharmaceuticals International, plc's net worth?
Kiniksa Pharmaceuticals International, plc has a market value (market cap) of $7.4B at the latest share price, and shareholders' equity of $710.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Kiniksa Pharmaceuticals International, plc profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $109.6M on revenue of $946M, a net margin of 11.6%.
How much revenue does Kiniksa Pharmaceuticals International, plc make?
Over the twelve months to September 30, 2026 Kiniksa Pharmaceuticals International, plc reported revenue of $946M. That is 58.2% more than a year earlier.
When did Kiniksa Pharmaceuticals International, plc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 27, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 6, 2026.
When is Kiniksa Pharmaceuticals International, plc's next earnings report?
Kiniksa Pharmaceuticals International, plc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare KNSA with
Follow KNSA
Get an email when Kiniksa Pharmaceuticals International, plc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Kiniksa Pharmaceuticals International, plc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.